Management

Dr. Alfred Hansel

Dr. Alfred Hansel

Biologist - CEO

Dr. Alfred Hansel, together with Dr. Martina Schmitz, has been leading oncgnostics GmbH since its foundation in February 2012. As CEO, he is responsible for the business development of oncgnostics GmbH. After his PhD in molecular microbiology (University of Freiburg i. Br.), he gained many years of experience in project management by working at domestic and foreign university institutions, as well as operational experience in industry in the business areas of product development, sales and marketing. The spin-off of oncgnostics GmbH is based on his scientific work in the functional area "Gynecological Molecular Biology", as well as a project group, which he led.

Dr. Martina Schmitz

Dr. Martina Schmitz

Biochemist - CSO

As scientific head, Dr. Martina Schmitz has been responsible for the development and registration of oncgnostics’ diagnostic tests based on epigenetic markers from the very beginning. Already in her scientific work she has gained extensive experience in diagnostics development, which she then has extended tremendously while leading the R&D team during CE IVD registration of oncgnostics first diagnostic products. From her scientific work at the Gynaecologic Molecular Biology unit, University hospital Jena (head Prof. Matthias Dürst) she has profound knowledge concerning the biological mechanisms underlying cervical cancer.

Dr. Peter Haug

Dr. Peter Haug

Chemist, economist - head of business development, licensing

Dr. Haug has more than ten years of pharma industry experience, where he was responsible for contracting, cooperations as well as acquisition of other companies, with a business volume of more than 250 million euro and 1500 employees (successful negotiations with AstraZeneca, Bristol-Myers, Genzyme, Roche). Since 2011 Peter is active as a founding angel, with focus on young companies, with whom he co-operates as a co-founder and manager.

Dr. Haug has more than 10 years of pharma industry experience, where he was responsible for contracting, cooperations as well as acquisition of other companies, with a business volume of >250 m € and 1500 employees (successful negotiations with AstraZeneca, Bristol-Myers, Genzyme, Roche). Since 2011 Peter is active as a founding angel, with focus on young companies, with whom he co-operates as co-founder and manager.